Hypothermia After Cardiac Arrest - Effects on Myocardial Function and Inflammatory Response.

Inflammatory Response Clinical Trial

— IH3  

Official title:

Hypothermia After Cardiac Arrest - Effects on Myocardial Function and Inflammatory Response.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03743584
• Other study ID #: 2018/1057 C
• Status: Completed
• Phase: N/A
• Start date: November 8, 2018
• Est. completion date: July 20, 2020

Study information

• Verified date: September 2021
• Source: Oslo University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The on-going randomized clinical trial TTM2 (Target Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest, NCT02908308) investigates if there is a difference in mortality, neurological function or quality of life in comatose survivors after out-of-hospital cardiac arrest if treated (Group A) at target temperature of 33 oC or (Group B) by avoiding fever during the first 24 h.

In this sub study, the effect of different target temperatures on cardiac and circulatory physiology is evaluated by echocardiography and pulmonary artery catheter. Tissue damage after cardiac arrest in part is caused by an activation of different parts of the inflammatory system (reperfusion injury). This study investigates the effect of temperature management on inflammation and the link to the circulatory effects.

Description:

Hypothermia (HT) is used as an adjunctive treatment to improve outcome in comatose survivors of out-of-hospital cardiac arrest (OHCA). Optimal temperature is debated and in the TTM-trial (Target Temperature Management study), which randomized to management at either 33 degrees C or 36 degrees C for 24h after return of spontaneous circulation (ROSC), no difference in mortality or neurological outcome was shown. The TTM-2-trial (Target Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest, NCT02908308) was initiated to investigate if there is a difference in mortality, neurological function or quality of life between target temperature of 33 degrees C or avoiding fever in comatose patients after out-of-hospital cardiac arrest and meet some of the critique that was raised against the TTM-trial regarding the speed of induction of hypothermia, that both groups were treated at different degrees of hypothermia and that both groups could have benefitted from this intervention.

This study is a prospective sub-study to the TTM-2 trial investigating the cardiac and hemodynamic effects of different target temperatures using echocardiography and pulmonary artery catheter (PAC). Data will be harvested and echocardiographic registration will be made during the target temperature phase, upon rewarming and after 48-72 hours. There will be a follow-up echocardiographic examination at 6 months from randomization.

Ischemia/reperfusion (I/R) injury is a key challenge in myocardial infarction and cardiac arrest. In this study most patients will experience myocardial infarction affecting the heart only, while all patients will experience cardiac arrest affecting the whole body. A major determinant of long-term outcome is the degree of cell death due to stop of blood supply during ischemia and aggravation of organ damage during reperfusion caused by innate immune activation. In this study we will address the importance of the innate immune system in determining outcome and the interplay and dependency with cardiac function.

Blood samples will be collected at the same time points as echocardiography registrations and collection of hemodynamic data and analyzed post study cessation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: July 20, 2020
• Est. primary completion date: July 20, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Included in the TTM2-trial and treated at the Intensive Care Unit at Rikshospitalet, Oslo

• Out-of-hospital cardiac arrest of a presumed cardiac or unknown cause

• Sustained ROSC - de?ned as 20 minutes with signs of circulation without the need for chest compressions.

• Unconsciousness de?ned as not being able to obey verbal commands (FOUR-score motor response of <4) and no verbal response to pain after sustained ROSC.

• Eligible for intensive care without restrictions or limitations

• Inclusion within 180 minutes of ROSC

Exclusion Criteria:

• Not included in the TTM2-trial

• Unwitnessed cardiac arrest with an initial rhythm of asystole

• Temperature on admission <30°C.

• On ECMO prior to ROSC

• Obvious or suspected pregnancy

• Intracranial bleeding

• Severe chronic obstructive pulmonary disorder (COPD) with long-term home oxygen therapy"

Related Conditions & MeSH terms

• Heart Arrest
• Hypothermia
• Inflammatory Response
• Ischemia
• Ischemia Reperfusion Injury
• Out of Hospital Cardiac Arrest
• Out-of-Hospital Cardiac Arrest
• Reperfusion Injury

Intervention

Procedure:
• Targeted temperature management
Target temperature management at 33°C
• Standard care, early treatment of fever
Standard of care with early treatment of fever

Locations

Country	Name	City	State
Norway	Oslo University Hospital	Oslo

Sponsors (1)

Lead Sponsor	Collaborator
Oslo University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in wall motion score	Cardiac output	48 hours , 72 hours, 6 months
Primary	Plasma concentration of inflammatory markers	inflammatory markers to be specified (e.g. Complement system activation, pro-inflammatory cytokines like IL-6 expressed as nanogram/milliliter)	48 hours , 72 hours, 6 months
Secondary	Association between inflammatory response and cardiac function	Association of plasma concentration of inflammatory markers (nanogram/milliliter) and Cardiac output (liter/minute)	48 hours , 72 hours, 6 months